ACAD(Acadia Pharmaceuticals Inc.) · 财务报表

ACAD(Acadia Pharmaceuticals Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$484.14M$517.24M$726.44M$957.80M$1.07B
毛利润$473.30M$507.07M$684.80M$875.96M$982.51M
营业利润−$170.44M−$223.60M−$73.38M$230.79M$104.81M
净利润−$167.87M−$215.97M−$61.29M$226.45M$391.00M
经营现金流−$125.66M−$114.03M$16.70M$157.72M$109.84M
自由现金流−$126.78M−$114.03M$16.65M$157.20M$105.15M
摊薄每股收益$-1.05$-1.34$-0.37$1.36$2.30

Acadia Pharmaceuticals Inc. ACAD